Patients who were in remission and in follow-up at study closure. Includes patients who were in remission according to the investigator and on-study at the time of study closure. Patients are shaded according to ALK status. A consolidative SCT was performed in 8 patients, and 8 patients received no further therapy after completing brentuximab vedotin. Allo-SCT, allogeneic SCT; Auto-SCT, autologous SCT; EOS, end of study.